The modification and application precautions of the WHO classification of tumors of the central nervous system (fifth edition)

doi:10.3969/j.issn.1672-6731.2026.01.001

Abstract

Abstract: The fifth edition of the WHO classification of tumors of the central nervous system (CNS5, 2021) is based on the concept of precision medicine. CNS5 incorporates a large number of new molecular diagnostic indicators as well as more detailed clinical and molecular epidemiological follow-up data. Through this, CNS5 has formulated new schemes for reclassifying, sub-classifying, typing, sub-typing, grading, and/or renaming of CNS tumors, and also added a large number of new tumor entities, significantly improving the accuracy, reproducibility, and consistency of diagnosis. This article briefly describes the main modification and significance of CNS5 and the precautions for its application.

Key words: Central nervous system neoplasms, World Health Organization, The fifth edition (not in MeSH)

摘要： WHO中枢神经系统肿瘤分类第5版（CNS5，2021年）基于精准医学理念，引入大量新的分子诊断指标及更详细的临床和分子流行病学随访数据，籍此制定对中枢神经系统肿瘤重新分类、亚分类、分型、亚分型、分级和（或）重新命名的新方案，增加大量新的肿瘤实体，显著提升诊断的精确性、可重复性和一致性。本文简述CNS5的主要变更和意义及其应用注意事项。

关键词: 中枢神经系统肿瘤, 世界卫生组织, 第5版(非MeSH词)

CLC Number:

R739.4
R602

YU Shi-zhu, SUN Cui-yun. The modification and application precautions of the WHO classification of tumors of the central nervous system (fifth edition)[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2026, 26(1): 1-7.

于士柱, 孙翠云. WHO中枢神经系统肿瘤分类第5版变更及应用注意事项[J]. 中国现代神经疾病杂志, 2026, 26(1): 1-7.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2026.01.001

https://journal11.magtechjournal.com/cjcnn/EN/Y2026/V26/I1/1

References

[1] Zülch KJ. Principles of the new World Health Organization (WHO) classification of brain tumors[J]. Neuroradiology, 1980, 19:59-66.
[2] Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours[J]. Brain Pathol, 1993, 3:255-268.
[3] Kleihues P, Cavenee WK. World Health Organization classification of tumours: pathology and genetics of tumours of the nervous system [M]. Lyon: International Agency for Research on Cancer, 2000: 6-249.
[4] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system[M]. Lyon: International Agency for Research on Cancer, 2007: 8-247.
[5] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system[M]. Lyon: International Agency for Research on Cancer, 2016: 10-337.
[6] WHO Classification of Tumours Editorial Board. Central nervous system tumours: WHO classification of tumours, 5th edition, volume 6[M]. Lyon: International Agency for Research on Cancer, 2022: 7-421.
[7] WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours: WHO classification of tumours, 5th edition, volume 3[M]. Lyon: International Agency for Research on Cancer, 2020: 2-3.
[8] Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022, 36:1720-1748.
[9] Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors [J]. Endocr Pathol, 2022, 33:6-26.
[10] Hernandez-Prera JC, Riddle N, Gonzalez RS, Asa SL. Endocrine and neuroendocrine tumors: updates from the 5th edition of the World Health Organization "Blue Book"[J]. Arch Pathol Lab Med, 2025, 149:1114-1135.
[11] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neuro Oncol, 2021, 23:1231-1251.
[12] Sahm F, Aldape KD, Brastianos PK, Brat DJ, Dahiya S, von Deimling A, Giannini C, Gilbert MR, Louis DN, Raleigh DR, Reifenberger G, Santagata S, Sarkar C, Zadeh G, Wesseling P, Perry A. cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas[J]. Neuro Oncol, 2025, 27:319-330.
[13] Rodriguez EF, De Marchi F, Lokhandwala PM, Belchis D, Xian R, Gocke CD, Eshleman JR, Illei P, Li MT. IDH1 and IDH2 mutations in lung adenocarcinomas: evidences of subclonal evolution[J]. Cancer Med, 2020, 9:4386-4394.
[14] Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm[J]. Blood Cancer J, 2021, 11:107.
[15] Wesseling P, Capper D, Reifenberger G, Sarkar C, Hawkins C, Perry A, Kleinschmidt-DeMasters B, Komori T, Paulus W, Santosh V, van den Bent M, Weller M, Pfister SM, Tabori U, Figarella-Branger D, Orr BA, Louis DN. cIMPACT-NOW update 11: proposal on adaptation of diagnostic criteria for IDH-and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors [J]. Brain Pathol, 2025.[Epub ahead of print]

Please choose a citation manager

Content to export